{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SEAMARK","nct_id":"NCT05217446","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=seamark-nct05217446. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SEAMARK","arms":[{"description":"Participants receive pembrolizumab IV.","label":"Arm B: pembrolizumab","type":"ACTIVE_COMPARATOR"},{"description":"Participants receive encorafenib orally + cetuximab IV + pembrolizumab IV.","label":"Arm A: encorafenib, cetuximab and pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC","Merck KGaA, Darmstadt, Germany","Eli Lilly and Company"],"completion_date":{"date":"2027-01-26","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Cancer"],"enrollment":{"count":108,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Encorafenib","otherNames":["PF-07263896 LGX818 ONO-7702 W0090"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["Keytruda®, MK-3475"],"type":"BIOLOGICAL"}],"last_update":"2026-07-31","lead_sponsor":"Pfizer","official_title":"A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Duration of study, approximately 45 months"}],"references":[{"citation":"Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249. Epub 2023 Oct 10.","pmid":"37815847","type":"DERIVED"}],"start_date":{"date":"2022-07-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05217446"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/seamark-nct05217446"}